Targets › PRAME
8 programs from 7 companies in 13 trials: 11 Phase 1, 2 Phase 3; Oncology; next expected readout Nov 2026.
Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation. The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding. (UniProt, P78395)
Open in Phaseline: the race on PRAME, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immunocore | Brenetafusp (IMC-F106C) Immune-mobilizing monoclonal T cell receptor (ImmTAC) targeting PRAME-positive cancer cell | PRAME | Phase 3 | Advanced Melanoma; Select Advanced Solid Tumors | Oct 2027 |
| Immatics US | IMA203 (anzutresgene autoleucel, anzu-cel) PRAME-redirected CAR-T cell therapy | PRAME | Phase 3 | Melanoma, Cutaneous Malignant; Refractory Cancer; Cutaneous Melanoma | Jan 2028 |
| Catherine Bollard | Tumor associated antigen lymphocytes (TAA-T) Multi-antigen specific cytotoxic T lymphocytes targeting WT1, PRAME, and SURVIVIN | WT1, PRAME, SURVIVIN | Phase 1 | Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS; Brain Tumor | Nov 2026 |
| M.D. Anderson Cancer Center | PRAME-TCR-NK cells PRAME-specific T cell receptor (TCR) engineered natural killer cells | PRAME | Phase 1 | Lymphodepleting Chemotherapy; Phase 1 | Apr 2027 |
| Immunocore | IMC-P115C Half-life extended (HLE) ImmTAC targeting PRAME; engages T cells to recognize PRAME-presen | PRAME | Phase 1 | PRAME Positive | Sep 2027 |
| Neowise Biotechnology | NW-101C PRAME-targeted TCR-engineered T cells | PRAME | Phase 1 | Solid Metastatic Tumor | Dec 2028 |
| Children's National Research Institute | DNR-PRAME Tumor Antigen-specific T cells PRAME-specific T cells with dTβRII co-stimulation | PRAME | Phase 1 | Rhabdomyosarcoma | Dec 2041 |
| PDC*line Pharma SAS | PDC*lung01 Dendritic cell vaccine loaded with synthetic peptides from lung tumor antigens (NY-ESO-1, | PRAME, MAGEA3, MAGEA4 | Phase 1 | Non Small Cell Lung Cancer | – |
Advanced Melanoma (1) Select Advanced Solid Tumors (1) Solid Metastatic Tumor (1) Lymphodepleting Chemotherapy (1) Phase 1 (1) Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS (1) Brain Tumor (1) Non Small Cell Lung Cancer (1) Melanoma, Cutaneous Malignant (1) Refractory Cancer (1) Cutaneous Melanoma (1) PRAME Positive (1)
mixed (3), protein or peptide (2), small molecule (2), other (1)
Immunocore (2) Neowise Biotechnology (1) M.D. Anderson Cancer Center (1) Catherine Bollard (1) PDC*line Pharma SAS (1) Immatics US (1) Children's National Research Institute (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.